在中国市场上诺和诺德的司美格鲁肽糖尿病药物今年上半年的销售也出现11%左右的下滑。在财报公布后的投资人电话会上诺和诺德现

智通财经
Aug 06
在中国市场上诺和诺德的司美格鲁肽糖尿病药物今年上半年的销售也出现11%左右的下滑。在财报公布后的投资人电话会上诺和诺德现任国际业务副总裁、即将于8月7日接替周赋德出任CEO的齐亚尔·迈克·杜斯特达(Maziar Mike Doustdar)回应了投资人关于司美格鲁肽在中国市场上面临的竞争挑战。杜斯特达表示虽然中国GLP-1糖尿病药出现了下滑但减重药销售是逐步增长的。他解释称糖尿病药销量出现下滑是由于经销商库存发生的变化;而去年刚刚获批的司美格鲁肽减重药目前还在放量阶段尚未进一步下沉到二、三、四线城市。 (第一财经)。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10